Bevacizumab: New Standard for Non-Small Cell Lung Cancer?

Is bevacizumab a new standard of care for patients with unresectable non-small cell lung cancer who have good performance status? This question was raised in a debate at the European Congress on Lung Cancer held in Turin. Christian Manegold provided delegates with evidence from the AVAil and ECOG 4599 studies which underpin current approval of this anti-vascular endothelial growth factor (VEG-F) antibody. Nick Thatcher pointed out the limitations. They both talked with Peter Goodwin.